A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Phase 2 Primary Outcome Measure

  Measured over: Through 90 days after the last study treatment

• Phase 2 Primary Outcome Measure

  Measured over: From first dose until approximately 30 days after the last study treatment, assessed up to 3 years

• Phase 2 Primary Outcome measure

  Measured over: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

• Phase 2 Primary Outcome Measure

  Measured over: From first dose until end of treatment, assessed up to 3 years

• Phase 3 Primary Outcome Measure

  Measured over: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.

• Phase 3 Primary Outcome Measure

  Measured over: From date of randomization until the end of study, assessed up to 4 years

Changes Tremor has spotted